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Edited by Lukas HuberAbstract Glucocorticoids (GC) are common components in
chemotherapeutic protocols for lymphoid malignancies. GC-in-
duced apoptosis requires the intrinsic, BCL-2 family-regulated
pathway. Treatment of CCRF-CEM (T cell acute lymphoblastic
leukemia) cells with the GC, dexamethasone (Dex), activates
p38-mitogen activated protein kinase (p38-MAPK) and then
induces mRNA transcription and synthesis levels of BIM, a
BH3-only pro-apoptotic BCL-2 family member. Dex-induced
apoptosis is dramatically inhibited by downregulation of BIM
by shRNA or by pretreatment with a p38-MAPK inhibitor,
SB203580, which also reduces BIM induction. These ﬁndings
indicate that BIM induction through p38-MAPK activation is
a critical pathway in GC-induced cell death.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Programmed cell death (apoptosis) is a well-conserved ge-
netic pathway with basic tenets that appear to be common to
all metazoans. Defective control of this pathway is implicated
in disorders ranging from cancer and autoimmune diseases to
degenerative syndromes. Speciﬁc defects in the capacity to un-
dergo apoptosis, or in the upstream signal transduction path-
ways not only provide cancer cells with an intrinsic survival
advantage, but may also confer inherent resistance to chemo-
therapeutic drugs. Many chemotherapeutic drugs kill target
cells via the mitochondria-dependent, BCL-2 family-regulated
pathway. The BCL-2 family is characterized by the presence of
structural homology, termed BCL-2 homology (BH) domains.
The ‘‘multi-domain’’ BCL-2 family members either suppress
apoptosis (e.g., MCL-1, BCL-2, BCL-XL) or promote apopto-
sis (e.g., BAX, BAK), whereas the ‘‘BH3-only’’ subfamily
members identiﬁed to date (e.g., BAD, BID, BIM, PUMA)
function to promote cell death [1,2]. The BH3-only proteins
act by antagonizing the function of anti-apoptotic BCL-2 fam-
ily members and also by directly activating BAX/BAK func-
tion. It has become clear that BH3-only proteins are
essential initiators of programmed cell death and may be piv-
otal in certain types of cancer cell killing.*Corresponding author. Fax: +1 804 827 1276.
E-mail address: hharada@vcu.edu (H. Harada).
1 These authors contributed equally to this work.
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.05.031BIM (BCL-2-interacting mediator of cell death), a BH3-only
protein, can bemodulated at the transcriptional and post-trans-
lational levels (reviewed by [3,4]). Transcriptional control of
BIM can involve contributions from Jun N-terminal kinase
(JNK), phosphoinositide 3-kinase (PI3K), and extracellular sig-
nal-regulated kinase (ERK) pathways. It has been reported that
phosphorylation and subsequent stability changes followed by
ubiquitination can regulate BIM’s protein level.We have shown
that ERK-dependent phosphorylation of BIM in response to
survival factor inhibits BIM–BAX interaction and conse-
quently promotes survival [5]. Studies of BIM-deﬁcient mice/
cells indicate important roles of BIM in hematopoietic cell
homeostasis [6] and response to a variety of chemotherapeutic
drugs. It has been recently demonstrated that loss of BIM facil-
itates myc-induced tumorigenesis in B cells [7,8]. In humans,
Bim is a candidate tumor suppressor gene in mantle cell lym-
phoma [9]. BIM is required for apoptosis induced by Taxol,
dexamethasone, Gleevec, and histone deacetylase inhibitors
[4,10,11], indicating that this protein has a role in anticancer
therapy against human malignancies. However, the molecular
mechanisms of both BIM regulation and BIM’s role in down-
stream cell death machinery are not entirely clear.
Glucocorticoids (GC) are eﬀective agents for the treatment
of leukemia/lymphoma, including acute lymphoblastic leuke-
mia (ALL), multiple myeloma, chronic lymphocytic leukemia,
and non-Hodgkin’s lymphoma [12–15]. GC-induced apoptosis
requires the BCL-2 family-regulated pathway, but the up-
stream signaling pathways and participation and interaction
of downstream target molecules remain largely undeﬁned.
Studies of BIM- or PUMA (p53 upregulated modulator of
apoptosis)-deﬁcient mice/cells suggest that these BH3-only
proteins play important roles in dexamethasone (Dex)-induced
cell death in normal lymphocytes [6,16,17].
In this report, we used a T cell-ALL (T-ALL) cell line,
CCRF-CEM to study the molecular mechanisms of Dex-in-
duced cell death in malignant cells. We demonstrate that
Dex induced apoptosis is critically dependent upon upregula-
tion of BIM, which is primarily regulated at RNA level and
dependent upon p38-MAPK activation.2. Materials and methods
2.1. Cell line and culture
The human T-ALL cell line CCRF-CEM was purchased from the
American Tissue Culture Collection. The cells were cultured with
RPMI 1640 supplemented with 10% heat-inactivated fetal bovine ser-
um, streptomycin, and penicillin G at 37 C in a 5% CO2 incubator.blished by Elsevier B.V. All rights reserved.
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Dexamethasone, U0126, LY294002 and SB203580 were purchased
from Sigma. SP600125 was purchased from Calbiochem. Antibodies
were purchased as follows: BIM (202000) from Calbiochem, PUMA,
BAX, BAK, BCL-XL, b-tubulin, phospho-JNK, ERK, JNK, and
AKT from Santa Cruz Biotechnology, BCL-2 from Pharmingen,
MCL-1 from Stressgen, phospho-p38-MAPK, phospho-ERK, phos-
pho-AKT, and p38-MAPK from Cell Signaling Technology.
2.3. Western blot analyses
Whole cell lysates were prepared with lysis buﬀer [20 mM Tris (pH
7.4), 137 mM NaCl, 1 mM dithiothreitol (DTT), 1% CHAPS,
20 mM NaF, 10 mM b-glycerophosphate, and a protease inhibitor
cocktail (Sigma)]. Equal amounts of proteins were loaded on SDS–
PAGE, transferred to a nitrocellulose membrane, and analyzed by
immunoblotting.
2.4. Cell viability assay
Cell death was quantiﬁed by Annexin-V-FITC (Becton Dickinson)-
propidium iodide (PI, Sigma) staining according to the manufacturer’s




































Fig. 1. The expression of the BCL-2 family members with Dex treatment i
0.3 lM) for the indicated times. Equal amounts of total cell extracts were su
were treated with Dex (0.3 lM) or vehicle (0.1%DMSO) for the indicated
normalized with the value of 18S RNA at the same time point. The results
actinomycin D (Act D, 1 lg/ml) or cycloheximide (CHX, 10 lg/ml) for 30 m
RNAs were subjected to real-time PCR as (B). The results are the mean ± S.D
with vehicle (V) or Dex (D, 0.3 lM) for 16 h. Equal amounts of total cell extr
antibodies.2.5. Real-time PCR
Total RNAs were prepared using Trisol reagent (Invitrogen). Resid-
ual DNAs in the samples were removed by treatment with RNase-free
DNase I (Ambion) according to the manufacture’s protocol. Experi-
ments were performed in the Virginia Commonwealth University Nu-
cleic Acid Research Facility with the ABI Prism 7900 Sequence
Detection System (Applied Biosystems) using the TaqMan One Step
PCR Master Mix Reagents Kit. 18S rRNA was quantiﬁed as endoge-
nous control. A probe and primer set for BIM was purchased from
Applied Biosystems (Hs001982_m1).2.6. Plasmid construction and transfection
pSR-BIMwas constructed by inserting the target sequence for human
BIM (GenBank AF032457, nucleotide 37–56; GACCGAGAAGG-
TAGACAATT) into pSUPER.retro.puro (Oligoengine) according to
the manufacture’s protocol. As a control, a scrambled, non-speciﬁc se-
quence (AATTCTCCGAACGTGTCACGT) was inserted into the
same vector (pSR-con). Transfection was performed by electroporation
using a Bio-Rad electroporator. The cells were suspended in RPMI 1640
(4 · 106/400 ll) with 10 lg of DNA and electroporated in 0.4 cm cuv-
ettes at 300 V, 500 lF. Puromycin (2 lg/ml) selection to establish stable
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3.1. BIM is induced by dexamethasone treatment in
CCRF-CEM cells prior to the onset of apoptosis
Dex is an eﬀective drug against ALL and BIM is induced by
Dex (0.3 lM) treatment in the Dex-sensitive T-ALL cell line,
CCRF-CEM (CEM) (Fig. 1A). We examined the expression
of the BCL-2 family proteins before the onset of apoptosis,
which begins in this cell line at 24 h after treatment. Eight to
sixteen hours after treatment, all isoforms of BIM (BIMEL,
BIML, BIMS) are strongly induced and continue to increase
to 24 h (Fig. 1A). Non-malignant thymocytes from PUMA
(another BH3-only member)-deﬁcient mice are resistant to
Dex-induced apoptosis [16,17], but the expression of PUMA
is not much changed, suggesting this protein may not be essen-
tial for Dex-induced apoptosis in CEM cells. The overall
expression of the multi-domain pro-apoptotic eﬀectors, BAX
and BAK, are constant. We also examined the expression of
anti-apoptotic members, BCL-2, MCL-1 and BCL-XL. All
these anti-apoptotic BCL-2 family members also show con-
stant expression (Fig. 1A). Upregulation of BIM and constant
expression of BAX/BAK and anti-apoptotic BCL-2, MCL-1,
and BCL-XL are also observed in a Dex-sensitive multiple
myeloma cell line, MM.1S (data not shown). It has also been
shown that BIM is induced by Dex in CEM cells, murine T-cell
lymphoma cell lines, and human pre-B acute lymphoblastic
leukemia cells [18–21]. These results suggest that BIM induc-
tion is critical for apoptosis in leukemia and myeloma cells that
























control shBIM3.2. Dexamethasone-mediated BIM induction is
transcriptionally regulated
Accumulating evidence indicates that various external stim-
uli regulate BIM in several possible ways, both transcription-
ally and post-translationally, e.g. by phosphorylation. We
ﬁrst examined Bim mRNA expression and found that induc-
tion starts 4 h after Dex treatment and continues to increase
to 16–24 h (Fig. 1B). Bim mRNA induction is completely
inhibited by a transcription inhibitor, actinomycin D. How-
ever, treatment with a protein synthesis inhibitor, cyclohexi-
mide, augments Dex-induced Bim mRNA accumulation
(super-induction) (Fig. 1C), suggesting that de novo protein
synthesis is not required for the induction of Bim mRNA.
BIM protein induction is inhibited by actinomycin D or cyclo-
heximide (Fig. 1D), thus new BIM protein synthesis is required
for its accumulation. Similar observations have been reported
in previous studies [18,21]. These data indicate that Dex treat-
ment increases BIM levels mainly by new mRNA synthesis.control shBIM
Fig. 2. BIM is required for Dex-induced apoptosis in CEM cells.
(A) Upper panel: CEM cells were transfected with either pSR-BIM
(shBIM) or pSR-con (control). Puromycin-resistant clones were
established from each transfection. Cells were treated with Dex as
Fig. 1A. Equal amounts of total cell extracts were subjected to Western
blots with anti-BIM and anti-b-tubulin antibodies. Lower panel: equal
amounts of the same total cell extracts at 0 and 8 h after Dex treatment
used above were subjected to Western blots with anti-phospho-p38-
MAPK and anti-p38-MAPK antibodies. (B) The cells in Fig. 2A were
treated with vehicle (V) or Dex (D, 0.3 lM) and cell viabilities were
determined at the indicated time points by Annexin V-PI staining
followed by FACS analysis. Values represent the mean ± S.D. of
duplicates. We analyzed three independent clones and the results are
reproducible.3.3. BIM is required for dexamethasone-induced cell death in
CEM cells
To conﬁrm the signiﬁcance of BIM in Dex-induced apopto-
sis, we introduced a shBIM (short hairpin BIM) construct with
pSUPER.retro (pSR) vector into CEM cells to reduce the
expression of endogenous BIM. As a control, a scrambled,
non-speciﬁc shRNA construct was transfected. The expression
of BIM is strongly inhibited by shBIM (Fig. 2A, upper panel),
although both control and shBIM-expressing cells show similar
p38-MAPK activation (Fig. 2A, lower panel), indicating that
GC signaling is still intact (see below in detail). Cell death in
response to Dex treatment is also strongly reduced by theexpression of shBIM (Fig. 2B). These data indicate that BIM
is an essential molecule in Dex-induced apoptosis in CEM cells.
3.4. The activation of p38-MAPK is required for
dexamethasone-induced apoptosis and BIM induction
It has been reported that transcriptional regulation of BIM
can involve contributions from JNK PI3K/AKT pathways
[3,4]. Phosphorylation and activity of BIM is directly regu-
lated by ERK and JNK. The phosphorylation status of
BIM is not altered after Dex treatment, judged by unchanged
band-shift on SDS–PAGE (Fig. 1A) [5]. The expression level
3542 J. Lu et al. / FEBS Letters 580 (2006) 3539–3544and phosphorylation status of ERK, JNK and AKT all show
little change throughout the time course (Fig. 3A). In con-
trast, phosphorylation of p38-MAPK starts to increase at
4–8 h after Dex treatment compared to control (vehicle only),
although there is no signiﬁcant diﬀerence in p38-MAPK total
protein levels (Fig. 3A). Treatment with a p38-MAPK inhib-
itor, SB203580, dramatically reduces Dex-induced apoptosis
(Fig. 3B). The activation of p38-MAPK and the inhibition
of apoptosis with SB203580 are also observed in MM.1S, a
multiple myeloma cell line (data not shown). However, a
PI3K inhibitor, LY294002 does not aﬀect cell death by Dex
(Fig. 3B). Treatment with a JNK inhibitor, SP600125 kills
CEM cells even without Dex treatment. Treatment withp-p38
p38
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Fig. 3. The activation of p38-MAPK is required for Dex-induced apoptos
indicated times. Equal amounts of total cell extracts were subjected to W
phosphorylated p38-MAPK in each band was determined by scanning densito
the relative value is shown at the bottom of the panel. The results are r
experiments. (B) Kinase inhibitors [p38-MAPK inhibitor, SB203580 (10 lM)
PI3K inhibitor, LY294002 (10 lM)] were added 30 min before Dex treatmen
viability was determined with Annexin V-PI staining followed by FACS a
reproducible in two independent experiments. (C) CEM cells were treated w
amounts of total cell extracts were subjected to Western blots with the in
experiments. (D) CEM cells were pretreated with SB203580 and were treated
subjected to real-time PCR. Each value was normalized with the value of 1
triplicates. (E) CEM cells were pretreated with SB203580, followed by veh
MAPKAPK-2). Equal amounts of total cell extracts were subjected to Wester
of MAPKAPK-2, which is a direct substrate of p38-MAPK, was determin
independent experiments.either U0126 (a MEK inhibitor) or SP600125 plus Dex en-
hances Dex-induced apoptosis (Fig. 3B). We determined the
eﬀect of the kinase inhibitors that we used on p38-MAPK
phosphorylation. LY294002 shows no eﬀect on p38-MAPK
phosphorylation induced by Dex (Fig. 3C, lanes 2 and 4),
U0126 slightly reduces the p38-MAPK phosphorylation, but
the phosphorylation is still induced by Dex treatment
(Fig. 3C, lanes 2 and 6), and the amount of cell death paral-
lels BIM induction (Fig. 3B and C). SP600125 alone strongly
induces p38-MAPK phosphorylation in the absence of Dex
(Fig. 3C, lane 7) and phosphorylation does not increase with
Dex treatment (Fig. 3C, lane 8). BIM levels decrease with co-
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metric analysis of the X-ray ﬁlms using the NIH Image J program, and
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ith kinase inhibitors as (B) followed by Dex treatment for 16 h. Equal
dicated antibodies. The results are reproducible in two independent
with vehicle or Dex (0.3 lM) for the indicated times. Total RNAs were
8S RNA at the same time point. The results are the mean ± S.D. of
icle (V) or Dex (D, 0.3 lM) treatment for 16 h (for BIM) or 8 h (for
n blots with the indicated antibodies. As a control, the phosphorylation
ed to see the eﬀect of SB203580. The results are reproducible in two
J. Lu et al. / FEBS Letters 580 (2006) 3539–3544 3543is increased approximately additively (Fig. 3B). Thus, we
speculate that cell death with SP600125 is BIM-independent.
The activation of p38-MAPK by Dex and similar kinase
inhibitor studies have also been reported in Dex-sensitive
CEM clones [22]. In conjunction with the inhibition of apop-
tosis, Bim mRNA and protein induction is partially reduced
by SB203580 (Fig. 3D and E). As a control, SB203580 inhib-
its Dex-induced phosphorylation of MAPKAPK-2, a direct
substrate of p38-MAPK (Fig. 3E). We also tested another
p38-MAPK inhibitor, SB 202190, and the results are similar
(data not shown). Taken together, the modulation of p38-
MAPK activity correlates with BIM induction and apoptosis,
indicating that p38-MAPK activation is required for BIM
induction and consequent apoptosis with Dex treatment.
However, cells expressing a shBIM construct are resistant
to Dex-induced apoptosis, but still show Dex-induced p38-
MAPK activation (Fig. 2A), suggesting that the activation
of p38-MAPK alone is not suﬃcient to induce apoptosis by
Dex treatment. Although the activation of p38-MAPK is re-
duced by SB 203580 to the basal level, Bim mRNA and pro-
tein induction are not completely inhibited (Fig. 3D and E).
Thus, it is possible that a p38-MAPK-independent BIM
induction pathway also contributes the induction of Bim
mRNA and protein.
It has been recently shown that p38-MAPK phosphorylates
GC receptor (GR) and contributes to Dex-induced apoptosis
in CEM cells [22]. However, GR phosphorylation is observed
20 h after Dex treatment, which is well after the BIM induc-
tion (4 h). Clearly GR phosphorylation cannot cause BIM
upregulation. Thus, we speculate that p38-MAPK ﬁrst in-
duces BIM expression, initiates apoptosis, and then phos-
phorylates GR to reactivate the cell death pathway. To
date, several signaling pathways and transcription factors
have been identiﬁed to regulate Bim mRNA, such as PI3K/
Akt/FOXO (Forkhead box O), JNK/c-Jun, and c-myc
[3,4,7,8]. However, we did not detect any changes in nuclear
FOXO levels initiated by Dex (unpublished data). Although
we do see increases in c-JUN levels, this induction appears
to be independent of p38-MAPK activation (unpublished
data). c-myc is known to be downregulated by Dex treatment
in CEM cells [23]. Therefore, other transcription factors
might be activated by p38-MAPK and contribute to Bim
mRNA induction. This could be a novel mode of BIM tran-
scriptional regulation.
In conclusion, we ﬁnd a critical signaling pathway for
GC-induced apoptosis, Dex-GR-p38-MAPK-BIM. It has re-
cently been published that the Bim gene is induced in child-
hood ALL patients sensitive to Dex treatment [18]. Our
results in CCRF-CEM model system also suggest that
BIM may be a primary GC target molecule to induce cell
death. GC resistant leukemia and myeloma are often associ-
ated with GC receptor defects. Precise delineation of the
pathway downstream might enable bypassing the receptor
to target downstream molecules that can initiate apoptosis
in cells with non-functional GC receptors. Understanding
the role of BIM in GC response could help develop new
therapeutic strategies to combat GC resistant leukemia/
myeloma.
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